Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition

Core Insights - BioMarin Pharmaceuticals Inc. (BMRN) is recognized as the second most promising gene editing stock according to analysts [1] - BMRN announced an acquisition of Amicus Therapeutics for approximately $4.8 billion, paying $14.50 per share, which enhances its position in rare metabolic diseases [2] - The acquisition is expected to close in Q2 2026 and will be accretive to non-GAAP earnings per share within 12 months, with substantial accretion beginning in 2027 [3] Financial Impact - The deal adds two marketed therapies from Amicus: Galafold for Fabry disease and the Pombiliti + Opfolda regimen for Pompe disease, which generated about $599 million in combined revenues over the past four quarters [2] - Analysts have a positive consensus on BMRN with an average price target near $88, indicating significant upside potential [4] Strategic Fit - Analysts from Leerink Partners, Oppenheimer, and Needham praised the strategic fit of the acquisition, highlighting its synergy with BMRN's global infrastructure and enzyme therapy focus [4] - The acquisition is expected to boost sales and long-term growth for BMRN [4] Company Overview - BioMarin Pharmaceuticals Inc. is a leader in genetics-centric biotechnology, focusing on turning genetic discoveries into therapies, particularly through gene therapy for rare genetic diseases [5]